Why the study?
Does co-treatment with CYP3A4-metabolized statins (atorvastatin or simvastatin) attenuate the platelet inhibitory effect of clopidogrel compared to a non-CYP3A4 metabolized statin (rosuvastatin) in patients with coronary artery disease?
Does co-treatment with CYP3A4-metabolized statins (atorvastatin or simvastatin) attenuate the platelet inhibitory effect of clopidogrel compared to a non-CYP3A4 metabolized statin (rosuvastatin) in patients with coronary artery disease?
Co-administration of CYP3A4-metabolized statins (atorvastatin, simvastatin) does not attenuate the antiplatelet efficacy of clopidogrel compared to non-CYP3A4 statins (rosuvastatin).
Answers are grounded in this paper and cite their sources.
Co-administration of atorvastatin or simvastatin does not attenuate clopidogrel's antiplatelet effect; confirms no clinically relevant CYP3A4 interaction in CAD.
OBJECTIVES: Possible interactions between clopidogrel and atorvastatin, simvastatin or rosuvastatin (a 'non-CYP3A4' metabolized statin) were investigated in a randomized prospective study using sensitive and specific ex vivo platelet function tests. METHODS: Patients with coronary artery disease participating in a double-blind study comparing lipid-lowering effects of atorvastatin (20-80 mg OD; n = 22) and rosuvastatin (10-40 mg OD; n = 24) were studied before and after 2 weeks treatment with clopidogrel 75 mg OD after completed statin dose titration. In addition, 23 patients were randomized to open-label simvastatin 40 mg OD. RESULTS: Clopidogrel inhibited 10 mumol L(-1) ADP-induced platelet aggregation by 40 +/- 27%, 57 +/- 28% and 51 +/- 29%, respectively, in patients on rosuvastatin, atorvastatin and simvastatin treatment. The other platelet tests yielded similar results. No dose-dependent effects of rosuvastatin or atorvastatin co-treatment on clopidogrel efficacy were observed. CONCLUSIONS: Treatment with CYP3A4 metabolized statins, atorvastatin or simvastatin, did not attenuate the platelet inhibitory effect of clopidogrel maintenance treatment compared with the non-CYP3A4 metabolized, rosuvastatin.
No takes yet. Share an insight, caveat, or question.
Malmström et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: